Covidien to market Vida Diagnostics' Apollo lung imaging system alongside its iLogic pulmonary navigation system.
Covidien (NYSE:COV) and Vida Diagnostics inked a deal for distribution of Vida's Apollo pulmonary imaging system.
The move is aimed at complimenting Mansfield, Mass.-based Covidien's pulmonary portfolio, including its i-Logic lung navigation system.
Abiomed shares slid 4% yesterday but are clawing their way back this morning after analysts at Piper Jaffray downgraded their rating on the medical device company.
Abiomed (NSDQ:ABMD) shares clawed back some of the nearly 4% lost yesterday as investors reacted to a downgrade by analysts at Piper Jaffray.
The Danvers, Mass.-based medical device company's stock fell from a $17.20-per-share close April 8 to end yesterday at $16.52 per share, a more than 3.9% decline. ABMD shares were trading at $16.98 apiece as of about 11 this morning, however, up 2.8%.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
The FDA approves Johnson & Johnson's 1st-of-a-kind Invokana diabetes drug, designed to flush unabsorbed sugar from the bloodstream.
The FDA approved a 1st-of-its-kind treatment for Type 2 diabetes, Johnson & Johnson's (NYSE:JNJ) Invokana, with the federal watchdog agency citing it as a pioneer in a new class of diabetes drug.
A federal judge awards $177 million to Covidien in a patent infringement lawsuit with Johnson & Johnson's Ethicon Endo-Surgery subsidiary over ultrasonic scalpel technology.
UPDATED March 29, 2013, with comment from Covidien.
Covidien CFO Charles Dockendorff says there's not much room for growth in biologic tissue mesh for hernia repair, a product the company acquired in 2008.
Covidien's (NYSE:COV) biologic hernia mesh product has hit a "brick wall," according to CFO Charles Dockendorff, but does that mean the company is looking to move on from the product it dropped more than $80 million to acquire?
Covidien closes enrollment in a pair of clinical trials, Visibility and Durability, examining its iliac stents for treating peripheral artery disease.
Covidien (NYSE:COV) said it closed enrollment in a pair of its Visibility and Durability iliac stent clinical studies.
The prospective, multinational studies are designed to compare balloon stents with self-expanding stents in the iliac arteries for treating peripheral artery disease.